Pharmaceuticals and Biotech

RxCelerate Establishes Venture Capital Division and Makes First Investment in US Metabolic Disease Company

by

RxCelerate, a leading international out-sourced drug discovery and development platform, announced today that it has established a venture capital fund, RxCapital, to invest in companies developing new therapeutics for significant unmet medical needs. “RxCelerate has a world-class team discovering and developing exciting new medicines for our clients,” said Dr. Jill Reckless, Chief Executive at RxCelerate, … Read more

BenchSci Expands Board of Directors With Appointment of Life Sciences, Tech, and Healthcare Leader Luba Greenwood

by

BenchSci, an emerging global leader in machine learning applications for novel medicine development, today announced that Luba Greenwood has joined its board of directors. Greenwood is a life sciences and biotech expert who lectures at Harvard University in the School of Engineering and Applied Sciences. She recently served as an executive at Google Life Sciences … Read more

Dr. Alessio Fasano Joins Nemysis Ltd’s Scientific Advisory Board

by

A pediatric gastroenterologist, Alessio Fasano, MD, is head of the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital (MGH) and professor of nutrition at the Harvard T.H. Chan School of Public Health. In 2000, his group discovered zonulin, a protein that regulates intestinal tight junctions and is associated with gut dysbiosis. His basic … Read more

Aronora Reports Positive Topline Data From Phase 2 Study of AB023 in Hemodialysis Patients

by

Aronora Inc., a clinical stage biotechnology company developing paradigm shifting therapies for serious hematologic diseases, today announced positive topline data from the Company’s randomized placebo-controlled phase 2 clinical trial testing AB023 in end-stage renal disease patients on heparin-free hemodialysis. AB023 is a recombinant antibody that specifically inhibits reciprocal activation of coagulation factors XI (FXI) and XII … Read more

Fourth Power Labs Announces National Launch of Exclusive Hemp-Derived, THC-Free CBD Products for Medical Professionals and Their Patients

by

Fourth Power Labs today announced it will begin offering pharmaceutical-grade hemp-derived, THC-free CBD products to Medical Professionals and their patients across the United States, effective immediately. Their products are now available for purchase through its dedicated salesforce and e-commerce website www.FourthPowerLabs.com. Fourth Power Labs’ product formulations are developed by Ph.D. scientists and contain a unique cannabinoid … Read more

FOMAT Medical Research Partners With Santa Maria Gastroenterology Medical Group

by

End Q2, 2021, Nicholas Focil, CEO of FOMAT, and Igor J. Nastaskin, CEO of Santa Maria Gastroenterology Medical Group, solidified their professional relationship as both parties agreed to join forces. This is an exciting partnership as it broadens the reach of medical research across Central California, making hard-to-reach clinical trials readily available for hundreds of thousands of patients. … Read more

BenchSci Signifies Growth of Machine Learning Product Portfolio With Appointment of Chief Platform Officer

by

BenchSci, an emerging global leader in machine learning applications for novel medicine development, today announced the appointment of Eran Ben-Ari as Chief Platform Officer. Effective June 28, 2021, he will oversee the Product, Engineering, and Science teams.  Ben-Ari is a technology leader with 15 years of experience successfully leading product and engineering teams by combining … Read more

FDA Grants Priority Review for Levo Therapeutics’ New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome

by

Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for LV-101 (intranasal carbetocin) as a treatment for hyperphagia and behavioral distress associated with … Read more

Scailyte and Lexogen Create a Joint Biomarker Discovery Workflow for Precision Medicine Companies

by

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solutions, announce a strategic partnership. The companies will create a joint biomarker discovery workflow, leveraging Lexogen’s new single-cell RNA sequencing platform LUTHOR™ and Scailyte’s AI-driven analytics platform ScaiVision™. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to the … Read more

Beth Harper Named Chief Learning Officer at Pro-Ficiency

by

Pro-ficiency is pleased to announce the appointment of Beth Harper, BS, MBA, as the new Chief Learning Officer. As a well-recognized thought-leader in the industry, Harper brings her innovation and vision to the rapidly growing Pro-ficiency executive team. “Pro-ficiency is incredibly fortunate to add Beth Harper to our leadership team,” said Pro-ficiency CEO, Michael Raymer. … Read more